Peptide-Lipid Nanoparticles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticles face challenges in effectively delivering therapeutic and diagnostic agents due to issues with size control, impurities, encapsulation efficiency, and targeted delivery, leading to unwanted side effects and poor bioavailability.
Innovation Solution
Development of nanoparticles with a payload and a conjugate of specific peptide structures, combined with lipids, that have controlled particle sizes and low impurities, enhancing targeted delivery and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional nanoparticles are used for delivery, then therapeutic agents can be delivered to targets, but size control is poor and impurities are high leading to unwanted side effects
Solution Approach 1:
The patent modifies physical and chemical parameters of the nanoparticle system by using specific peptide sequences (e.g., apolipoprotein A-I mimetic) and controlling the R group variations in the conjugate structure. These parameter changes enable precise control over particle size (5-350 nm range) and surface properties, thereby improving manufacturing precision and reducing harmful side effects through better size control and purity
Solution Approach 2:
The invention creates composite nanoparticle structures combining peptide-based conjugates with hydrophobic payloads and lipids. The conjugate structure comprises a peptide moiety (A) linked to a hydrophobic group (R), forming a composite material that self-assembles into nanoparticles with controlled morphology and size distribution, achieving both precision and reduced toxicity
2Reliability
If nanoparticles are used for targeted delivery, then delivery efficiency can be improved, but encapsulation efficiency is poor leading to low bioavailability
Solution Approach 1:
The patent applies local quality by creating distinct regions within the nanoparticle structure: hydrophilic peptide regions for stability and targeting, and hydrophobic core regions (formed by R groups and payload) for high encapsulation efficiency. This local differentiation allows the nanoparticle to simultaneously achieve reliable targeted delivery and high drug loading capacity
Solution Approach 2:
The peptide-conjugate acts as an intermediary structure that mediates between the hydrophobic therapeutic payload and the aqueous biological environment. The conjugate's amphiphilic nature (hydrophilic peptide + hydrophobic R group) enables efficient encapsulation of hydrophobic drugs while maintaining colloidal stability and bioavailability in physiological conditions
3Quantity of substance
If nanoparticles are synthesized with high payload loading, then therapeutic effect can be enhanced, but impurities increase leading to reduced safety
Solution Approach 1:
The patent segments the nanoparticle into distinct functional components: the peptide-based conjugate structure (with defined A and R groups) and the hydrophobic payload. This segmentation allows for modular design where the conjugate acts as a standardized carrier that can consistently encapsulate various payloads, achieving high loading efficiency while maintaining purity through controlled self-assembly and reduced aggregation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles achieve improved delivery and bioavailability of therapeutic and diagnostic agents, reducing side effects and enhancing therapeutic effects by controlling particle size and impurities.
Implementation Method 1
R is C1-40 alkyl, C2-40 alkenyl, or C2-40 alkynyl
Implementation Method 2
nanoparticles, comprising: (a) a payload; and (b) a conjugate having the structure of formula (I)
Data Source
AI summary
The present disclosure relates to nanoparticles comprising a payload and a conjugate having the structure of formula (I):